Eli Lilly reached a market capitalization of $1 trillion on Friday, becoming the first pharmaceutical company to join the exclusive group previously dominated only by tech giants, Reuters reports.
The milestone reflects the company’s extraordinary rise, driven by soaring global demand for anti-obesity treatments — a sector that has rapidly evolved from niche to one of the most profitable categories in healthcare.
Eli Lilly’s shares have surged more than 35% in 2025, supported by the rapid expansion of the weight-loss drug market. Although Novo Nordisk pioneered the field, Lilly’s medications — Mounjaro and Zepbound — have gained increasing popularity for their strong clinical results.
Read also: Norofert officially opens its new production facility in Brazil
According to the latest financial data, the company generated $10.09 billion from its diabetes and weight-loss portfolio, accounting for more than half of its total revenues of $17.6 billion. This shift underscores how central obesity treatments have become to Eli Lilly’s strategy.
Wall Street analysts estimate that the global weight-loss drug market could reach $150 billion by 2030, with Eli Lilly and Novo Nordisk expected to dominate most forecasted sales.
Crossing the $1 trillion mark highlights a broader transformation within the pharmaceutical industry: anti-obesity medicines are no longer viewed solely as therapeutic products but as major commercial drivers in a world increasingly focused on health and lifestyle.
Photo: CTech
